These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 9324281)
1. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. O'Brien S; Kantarjian H; Beran M; Koller C; Talpaz M; Lerner S; Keating MJ Leukemia; 1997 Oct; 11(10):1631-5. PubMed ID: 9324281 [TBL] [Abstract][Full Text] [Related]
2. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Anaissie EJ; Kontoyiannis DP; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating MJ Ann Intern Med; 1998 Oct; 129(7):559-66. PubMed ID: 9758577 [TBL] [Abstract][Full Text] [Related]
3. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125 [TBL] [Abstract][Full Text] [Related]
4. Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab. Gruber M; Fleiss K; Porpaczy E; Skrabs C; Hauswirth AW; Gaiger A; Vanura K; Heintel D; Shehata M; Einberger C; Thalhammer R; Fonatsch C; Jäger U Ann Hematol; 2011 Oct; 90(10):1131-6. PubMed ID: 21617923 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Südhoff T; Arning M; Schneider W Leukemia; 1997 Apr; 11 Suppl 2():S38-41. PubMed ID: 9178837 [TBL] [Abstract][Full Text] [Related]
6. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226 [TBL] [Abstract][Full Text] [Related]
7. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating MJ Leukemia; 1995 Sep; 9(9):1444-9. PubMed ID: 7658710 [TBL] [Abstract][Full Text] [Related]
8. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer. Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893 [TBL] [Abstract][Full Text] [Related]
10. [Prevention and treatment of febrile neutropenia]. Montemurro F; Gallicchio M; Aglietta M Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330 [TBL] [Abstract][Full Text] [Related]
12. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528 [TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Bergmann L; Fenchel K; Jahn B; Mitrou PS; Hoelzer D Ann Oncol; 1993 May; 4(5):371-5. PubMed ID: 8353071 [TBL] [Abstract][Full Text] [Related]
14. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia. Ghalaut PS; Sen R; Dixit G J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972 [TBL] [Abstract][Full Text] [Related]
15. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625 [TBL] [Abstract][Full Text] [Related]
16. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer. Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799 [TBL] [Abstract][Full Text] [Related]